Promoter holding
64.27%
SP
Sun Pharma Laboratories Limited - Due diligence report
A 360° intelligence report on Sun Pharma Laboratories Limited: trust score, financial health, credit view, compliance, directors, growth and…
Sun Pharma Laboratories Limited — 360° Intelligence Report
Generated from MCA filings & public records84/100
Trust Score
Low Risk
Sun Pharma Laboratories Limited is assessed as Low Risk with a Trust Score of 84/100. Sun Pharma Laboratories Limited is an active public limited indian non-government company incorporated in 1997, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and low financial risk profile.
Report generated on 13 Jun 2026 from the latest processed filings. Sun Pharma Laboratories Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
84/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
72/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
90/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
75/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- No open charges - unencumbered balance sheet.
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (A1).
Charges position: 0 open (-) · 0 satisfied (-).
Compliance Score: 72/100 Moderate
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 3 court forum(s).
- Delayed payments to MSME suppliers disclosed (445 disclosure(s)).
- 27 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 75/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PRITI PARAS SAVLA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MEETAL SHARAD SAMPAT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAKESHCHANDRA JAGDISHPRASAD SINHA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KIRTI WARDHAMAN GANORKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| CHINNADHARAVARAM SUNDARESAN MURALIDHARAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Kirti Wardhaman Ganorkar | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JAYASHREE SATAGOPAN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MEETAL SHARAD SAMPAT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GAUTAM BHAILAL DOSHI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 9 directors on the board.
- No disqualified or deactivated DINs.
- 4 director exits in 3 years - high churn.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2024 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Sun Pharmaceutical Industries Limited
Subsidiaries
4
Group entities
6
Capital events
2 allotment(s) · 1 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Realstone Infra Limited | Subsidiary Company | 74.00% |
| Sun Pharma Distributors Limited | Subsidiary Company | 74.00% |
| Sun Pharmaceutical Medicare Limited | Subsidiary Company | 74.00% |
| Universal Enterprises Private Limited | Subsidiary Company | 74.00% |
| Sun Pharmaceutical Industries Limited | Holding Company | 74.00% |
| Vivaldis Health And Foods Private Limited | Subsidiary Company | 74.00% |
| Trumpcard Advisors And Finvest Llp | Associate Company | 74.00% |
| Ezerx Health Tech Private Limited | Associate Company | 74.00% |
| Remidio Innovative Solutions Private Limited | Associate Company | 74.00% |
| Generic Solar Power Llp | Associate Company | 74.00% |
Key managerial personnel: KIRTI WARDHAMAN GANORKAR (CEO) · CHINNADHARAVARAM SUNDARESAN MURALIDHARAN (CFO) · Kirti Wardhaman Ganorkar (Whole-time director) · JAYASHREE SATAGOPAN (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 90 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Asset base grew 24% - capacity expansion.
Net margin improved to 0.86.
Operating for 29+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
MSME payment delays disclosed - latest outstanding 3.79 cr.
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence81/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment88/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance record supports lending.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Jul 2025
Last AGM held
Annual general meeting
01 Jul 2025
Director appointed
JAYASHREE SATAGOPAN (CFO)
Director ceased
CHINNADHARAVARAM SUNDARESAN MURALIDHARAN
31 Mar 2025
Latest balance sheet
Filed with ROC
26 Aug 2024
Director ceased
RAKESHCHANDRA JAGDISHPRASAD SINHA
21 May 2024
Director appointed
Kirti Wardhaman Ganorkar (Whole-time director)
Director ceased
Kirti Wardhaman Ganorkar
23 Apr 2024
Director appointed
RAKESHCHANDRA JAGDISHPRASAD SINHA (Director)
30 Aug 2023
Director ceased
PRITI PARAS SAVLA
31 Mar 2023
Share transfer (FY 2023)
801.00000000 shares to MEETAL SAMPAT
01 Nov 2022
Director ceased
RAMA BIJAPURKAR
31 Oct 2022
Director appointed
PRITI PARAS SAVLA (Director)
27 May 2022
Director appointed
MEETAL SHARAD SAMPAT (Company Secretary)
08 Feb 2022
Director ceased
GAUTAM BHAILAL DOSHI
20 Oct 2021
Director appointed
GAUTAM BHAILAL DOSHI (Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Net worth is positive.
9 active director(s) / partner(s); board looks stable and experienced.
27 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 4 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of A1 from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Msn Laboratories | U24239TG2003PTC041583 | Hyderabad, Telangana, India |
| Alkem Laboratories | L00305MH1973PLC174201 | Mumbai, Maharashtra, India |
| Seruminstitute | U80903PN1984PTC032945 | Pune, Maharashtra, India |
| Tergene Biotech | L24239TG1986PLC015190 | Hyderabad, Telangana, India |
| Haldiapetrochemicals | U24100WB2015PLC205383 | Kolkata, West Bengal, India |
| Lupin | L24100MH1983PLC029442 | Mumbai, Maharashtra, India |
| Grasim | L17124MP1947PLC000410 | Ujjain, Madhya Pradesh, India |
| Sleek | L24220MH1945PLC004598 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Sun Pharma Laboratories Limited before audits and certifications: compliance score 72/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Sun Pharma Laboratories Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Sun Pharma Laboratories Limited - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 84/100, distress signals and MSME payment-delay disclosures - know whether Sun Pharma Laboratories Limited pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Sun Pharma Laboratories Limited - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Sun Pharma Laboratories Limited an active company?
Sun Pharma Laboratories Limited has MCA status “Active” with a compliance score of 72/100 (Moderate).
Is Sun Pharma Laboratories Limited financially healthy?
Sun Pharma Laboratories Limited has a Financial Health Score of 90/100 (Low Risk) based on its filed financial statements.
Should I do business with Sun Pharma Laboratories Limited?
Its overall Trust Score is 84/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Sun Pharma Laboratories Limited?
The ultimate holding entity is Sun Pharmaceutical Industries Limited. 9 active director(s) are on record.
Does Sun Pharma Laboratories Limited have loans or charges against its assets?
No charges are registered against this company - an unencumbered balance sheet.
Is Sun Pharma Laboratories Limited up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 72/100 (Moderate).
Is it risky to lend to Sun Pharma Laboratories Limited?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
